ArticlePharmaceuticals (Basel, Switzerland)2021
Sub-Micromolar Inhibition of SARS-CoV-2 3CLpro by Natural Compounds.
Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Importin α3 Is Tolerant to Nuclear Localization Signal Chirality.International journal of molecular sciences · 2025Article
- New insights in the mechanism of the SARS-CoV-2 MScientific reports · 2024Article
- Potential Beneficial Effects of Naringin and Naringenin on Long COVID-A Review of the Literature.Microorganisms · 2024Review
- COVID-19 in Dental Practice Is Prevented by Eugenol Responsible for the Ambient Odor Specific to Dental Offices: Possibility and Speculation.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Review
- Dissecting CYP1A2 Activation by Arylalkanoic Acid Prodrugs toward the Development of Anti-Inflammatory Agents.International journal of molecular sciences · 2023Article
- Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 MPharmaceuticals (Basel, Switzerland) · 2023Article
- Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview.Molecules (Basel, Switzerland) · 2023Review
- Computational investigation on the antioxidant activities and on the MFrontiers in chemistry · 2023Article
- The SARS-CoV-2 main protease (MMedComm · 2022Review
- Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1.Frontiers in cardiovascular medicine · 2022Article
- Evaluating In Silico the Potential Health and Environmental Benefits of Houseplant Volatile Organic Compounds for an Emerging 'Indoor Forest Bathing' Approach.International journal of environmental research and public health · 2021Article
- Precursors of Viral Proteases as Distinct Drug Targets.Viruses · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Inhibiting the main protease 3CLpro is the most common strategy in the search for antiviral drugs to fight the infection from SARS-CoV-2. We report that the natural compound eugenol is able to hamper in vitro the enzymatic activity of 3CLpro, the SARS-CoV-2 main protease, with an inhibition constant in the sub-micromolar range (K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.